Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18F BMS 986229

Next Previous
Drug Profile

18F BMS 986229

Alternative Names: [18F] BMS 986229; PD-L1 Macrocyclic Peptide PET Tracer - Bristol Myers Squibb

Latest Information Update: 17 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb; PeptiDream
  • Developer Bristol-Myers Squibb; Memorial Sloan-Kettering Cancer Center
  • Class Imaging agents; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastric cancer; Oesophageal cancer

Most Recent Events

  • 17 Jul 2025 18F BMS 986229 is still in phase I trials for Gastric cancer and Oesophageal cancer (Diagnosis) in USA (IV, Injection) (Peptidream pipeline, July 2025)
  • 18 Jan 2024 Efficacy, adverse events and biomarker data from a phase I trial in Gastric cancer and Esophageal cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 14 Dec 2022 Phase I trial is still ongoing for Gastric cancer (Diagnosis) and Oesophageal cancer (Diagnosis) in USA (IV) (NCT04161781)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top